498 related articles for article (PubMed ID: 33982774)
1. Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor‑mediated signaling.
Lu S; Dong Z
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 33982774
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
Liang J; Wang L; Poluben L; Nouri M; Arai S; Xie L; Voznesensky OS; Cato L; Yuan X; Russo JW; Long HW; Brown M; Chen S; Balk SP
Cancer Lett; 2021 Oct; 519():172-184. PubMed ID: 34256096
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
4. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor Upregulates Mucosa-Associated Lymphoid Tissue 1 to Induce NF-κB Activity via Androgen-Dependent and -Independent Pathways in Prostate Carcinoma Cells.
Chang KS; Chen ST; Sung HC; Hsu SY; Lin WY; Hou CP; Lin YH; Feng TH; Tsui KH; Juang HH
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047218
[TBL] [Abstract][Full Text] [Related]
6. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
7. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
8. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
Sun S; Sprenger CC; Vessella RL; Haugk K; Soriano K; Mostaghel EA; Page ST; Coleman IM; Nguyen HM; Sun H; Nelson PS; Plymate SR
J Clin Invest; 2010 Aug; 120(8):2715-30. PubMed ID: 20644256
[TBL] [Abstract][Full Text] [Related]
9. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
10.
Jillson LK; Rider LC; Rodrigues LU; Romero L; Karimpour-Fard A; Nieto C; Gillette C; Torkko K; Danis E; Smith EE; Nolley R; Peehl DM; Lucia MS; Costello JC; Cramer SD
Mol Cancer Res; 2021 Jul; 19(7):1123-1136. PubMed ID: 33846123
[TBL] [Abstract][Full Text] [Related]
11. A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants.
Sun F; Indran IR; Zhang ZW; Tan MH; Li Y; Lim ZL; Hua R; Yang C; Soon FF; Li J; Xu HE; Cheung E; Yong EL
Carcinogenesis; 2015 Jul; 36(7):757-68. PubMed ID: 25908644
[TBL] [Abstract][Full Text] [Related]
12. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
13. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.
Puhr M; Hoefer J; Eigentler A; Dietrich D; van Leenders G; Uhl B; Hoogland M; Handle F; Schlick B; Neuwirt H; Sailer V; Kristiansen G; Klocker H; Culig Z
Oncogene; 2016 May; 35(18):2322-32. PubMed ID: 26257066
[TBL] [Abstract][Full Text] [Related]
14. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer.
Marín-Aguilera M; Jiménez N; Reig Ò; Montalbo R; Verma AK; Castellano G; Mengual L; Victoria I; Pereira MV; Milà-Guasch M; García-Recio S; Benítez-Ribas D; Cabezón R; González A; Juan M; Prat A; Mellado B
Cells; 2020 Jan; 9(1):. PubMed ID: 31947623
[TBL] [Abstract][Full Text] [Related]
16. LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation.
Chen L; Wang YY; Li D; Wang C; Wang SY; Shao SH; Zhu ZY; Zhao J; Zhang Y; Ruan Y; Han BM; Xia SJ; Jiang CY; Zhao FJ
Cancer Lett; 2021 Apr; 503():138-150. PubMed ID: 33503448
[TBL] [Abstract][Full Text] [Related]
17. Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
Li H; Mohamed AA; Sharad S; Umeda E; Song Y; Young D; Petrovics G; McLeod DG; Sesterhenn IA; Sreenath T; Dobi A; Srivastava S
Oncotarget; 2015 Jun; 6(17):15137-49. PubMed ID: 25883222
[TBL] [Abstract][Full Text] [Related]
18. Bakuchiol exhibits anti-metastasis activity through NF-κB cross-talk signaling with AR and ERβ in androgen-independent prostate cancer cells PC-3.
Miao L; Yun X; Tao R; Wang Y; Fan G; Zhu Y; Cai T; Zhu Z; Yan C; Gao X
J Pharmacol Sci; 2018 Sep; 138(1):1-8. PubMed ID: 30236540
[TBL] [Abstract][Full Text] [Related]
19. Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic Target.
Zalcman N; Gutreiman M; Shahar T; Weller M; Lavon I
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681618
[TBL] [Abstract][Full Text] [Related]
20. Expression profiles and functional associations of endogenous androgen receptor and caveolin-1 in prostate cancer cell lines.
Bennett NC; Hooper JD; Johnson DW; Gobe GC
Prostate; 2014 May; 74(5):478-87. PubMed ID: 24375805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
